Mesa Laboratories MLAB Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharmaceutical Development | $8.85M-29.9% | $14.37M+17.5% | $13.92M+17.3% | $11.49M-4.3% | $12.62M+3.5% | |
| Clinical Genomics | $12.18M+5.8% | $11.77M-7.1% | $11.14M-3.1% | $10.3M-9.7% | $11.51M+3.5% | |
| Gross Profit by Business | ||||||
| Biopharmaceutical Development | $5.2M-28.3% | $8.92M+18.3% | $8.13M+13.4% | $6.31M-20.8% | $7.25M-4.8% | |
| Clinical Genomics | $7.39M+16.9% | $7.11M+2.4% | $6.1M+3.2% | $5.43M-16.4% | $6.33M+2.5% | |
| Cost Of Revenue by Business | ||||||
| Biopharmaceutical Development | $3.65M-32.0% | $5.45M+16.1% | $5.79M+23.2% | $5.18M+27.9% | $5.37M+40.3% | |
| Clinical Genomics | $4.79M-7.6% | $4.65M-18.6% | $5.04M-9.8% | $4.87M-0.9% | $5.19M-18.7% | |
| Cost Of Revenue Other by Business | ||||||
| Biopharmaceutical Development | $3.2M-35.4% | $4.99M+16.0% | $5.35M+24.0% | $4.72M+29.0% | $4.95M+44.0% | |
| Clinical Genomics | $4.47M-7.4% | $4.33M-21.4% | $4.7M-8.2% | $4.52M+0.1% | $4.83M-4.0% | |
| Inventory Net by Business | ||||||
| Biopharmaceutical Development | $6.51M+32.0% | $5.89M— | $5.72M— | $5.94M— | $4.93M-21.7% | |
| Clinical Genomics | $8.32M-14.9% | $8.75M— | $9.1M— | $10.01M— | $9.78M-17.2% | |
| Cost Of Goods And Services Sold Depreciation by Business | ||||||
| Biopharmaceutical Development | $65K-13.3% | $88K+39.7% | $66K+65.0% | $89K+93.5% | $75K+33.9% | |
| Clinical Genomics | $127K-23.5% | $133K+600% | $152K-46.3% | $166K-21.7% | $166K-29.1% | |
| Goodwill by Business | ||||||
| Biopharmaceutical Development | $49.67M+3.0% | $50.82M— | $50.1M— | $49.84M— | $48.21M+3.6% | |
| Clinical Genomics | $17.12M+1.2% | $17.12M— | $17.08M— | $17.06M— | $16.93M-0.1% | |
| Cost Of Goods And Services Sold Amortization by Business | ||||||
| Biopharmaceutical Development | $386K+12.2% | $379K+12.1% | $375K+8.4% | $372K+7.8% | $344K+2.8% | |
| Clinical Genomics | $191K0.0% | $191K0.0% | $192K0.0% | $191K0.0% | $191K-82.8% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Clinical Genomics | $0+100% | $44K+1,567% | $17K+667% | $135K+4,600% | -$3K+96.0% | |
| Revenue by Product | ||||||
| Service | $12.2M+11.3% | $11.05M+8.0% | $11.29M+9.6% | $11.2M+1.0% | $10.96M+4.9% | |
| Revenue by Geography | ||||||
| CN | $4.06M-19.5% | $5.65M-10.7% | $5.32M-28.1% | $5.43M-17.2% | $5.04M-20.6% | |
| Other | $29.61M+14.3% | $29.59M+13.6% | $26.12M+16.8% | $26.47M+6.9% | $25.89M+2.1% | |
| US | $30.06M-3.7% | $29.89M-1.9% | $29.3M+4.4% | $27.65M+2.9% | $31.2M+14.7% | |
| Non-Current Assets by Geography | ||||||
| Non Us | $1.21M+3.8% | —— | —— | —— | $1.17M-3.2% | |
| SE | $10.86M-6.7% | —— | —— | —— | $11.63M+815% | |
| US | $29.89M+2.4% | —— | —— | —— | $29.2M-9.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
